Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment
- 1Division of Gastroenterology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
- 2Division of Nephrology, Department of Medicine, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
- Correspondence to Dr Florence Wong, Division of Gastroenterology, Department of Medicine, University of Toronto, 9N/983 Toronto General Hospital, 200 Elizabeth Street, Toronto M5G 2C4, Ontario, Canada;
Contributors FW and RR conceptualised and designed the study. NR was responsible for collecting the data and performed the data analysis. She also wrote the manuscript. All authors contributed to the intellectual contents, and approved the final version of the manuscript.
- Revised 2 July 2009
- Accepted 21 July 2009
- Published Online First 25 August 2009
Background The pathogenetic mechanism of hepatorenal syndrome (HRS) is paradoxical renal vasoconstriction consequent upon systemic and splanchnic arterial vasodilatation. Molecular adsorbent recirculating system (MARS) is a specialised form of dialysis that clears albumin-bound substances, including vasodilators, and therefore can potentially reduce systemic vasodilatation in cirrhosis.
Objective To assess the efficacy of MARS in improving systemic and renal haemodynamics in patients with cirrhosis with refractory ascites and type 1 HRS not responding to vasoconstrictor therapy.
Methods A pilot study was carried out in an academic teaching hospital. The study group comprised six patients with cirrhosis, refractory ascites and type 1 HRS not responding to vasoconstrictor treatment. All patients received 5 days of 6–8 h of MARS dialysis. The main outcome measures were pre-MARS and post-MARS measurements of glomerular filtration rate, renal blood flow, neurohormones, cytokines and nitric oxide (NO), as well as daily biochemistry, haematology and urinary volume.
Results There were no significant changes in systemic haemodynamics and GFR following MARS treatments, despite a significant reduction in NO concentrations (111.5±18.8 μmol/l pre-MARS, to 65.1±8.2 μmol/l post-MARS, p=0.05). There was a transient reduction in serum creatinine (p<0.05), Child–Pugh and MELD (Model End-Stage Liver Disease) scores with MARS, but no significant difference was observed in neurohormone and cytokine levels. Four of six patients died following MARS treatments.
Conclusions In patients with cirrhosis, refractory ascites and type 1 HRS not responding to vasoconstrictor treatment, MARS is ineffective in improving systemic haemodynamics and renal function despite reduction in NO levels, suggesting that vasodilatation in advanced cirrhosis is not due to excess systemic vasodilators alone. Transient reduction in serum creatinine indicates direct removal by MARS, and may not represent improved renal function.
Funding This study was supported by a grant awarded jointly to FW and RR by the Canadian Institutes of Health Research, Grant number: UOP-71655.
Competing interests None.
Ethics approval This study was conducted with the approval of the Ethics Committee, University Health Network, Toronto, Canada.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.